Navigation Links
Faruqi & Faruqi, LLP Announces Investigation of ZELTIQ Aesthetics, Inc.
Date:3/20/2012

NEW YORK, March 20, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at ZELTIQ Aesthetics, Inc. ("ZELTIQ" or the "Company") (NASDAQ: ZLTQ).   

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

Faruqi & Faruqi is investigating allegations that ZELTIQ executives misled investors by failing to disclose material information about the delayed sale of Company products and increased competition from a competitor's Liposonix business.

On March 6, 2012, shares of ZELTIQ plummeted after the Company announced fourth quarter 2011 sales and profits that fell well below analyst estimates. ZELTIQ reported a loss per share of $0.22, while analysts had been expecting a per share loss of only $0.09. In addition, ZELTIQ predicted 2012 sales in the range of $90 million to $94 million, well below analyst expectations of $114 million.

In the days following this extremely disappointing news, ZELTIQ's stock price lost nearly 47% of its value – falling from $11.11 per share on March 5, 2012, to only $5.66 per share on March 8, 2012.

Request more information now by clicking here: www.faruqilaw.com/ZLTQ

Take Action
If you purchased ZELTIQ securities and would like to discuss your legal rights, visit www.faruqilaw.com/ZLTQ. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding ZELTIQ's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential matter.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com  
Francis McConville, Esq.
fmcconville@faruqilaw.com  
Telephone: (877) 247-4292 or (212) 983-9330


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
2. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
3. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
4. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
5. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
6. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
7. Robbins & Myers Announces Regular Quarterly Cash Dividend
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
10. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
11. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... name the Creator responds to and which He does not. Yisrayl says with so ... one is the true name, but he says with a little Scripture, backed with a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA ... region. Côté has 20+ years of experience within the beauty industry, ranging from ... an array of high-end cosmetic brands, retail brands and outlets in Canada and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Christie Medical Holdings, Inc. ... alliance with B. Braun Medical Inc. , a leader in infusion therapy and ... with as many as 90 percent of hospital patients receiving a peripheral IV catheter ...
Breaking Medicine News(10 mins):